肝脏疾病患者组织因子抑制物检测意义  

Clinical significance of tissue factor pathway inhibitor detection in patients with liver diseases

作　　者：钟洪明[1] 朱顺强[2] 

机构地区：[1]福建医科大学附属第一医院检验科,福州350005 [2]福建医科大学医学技术与工程学院检验系,福州350005

出　　处：《国际检验医学杂志》2007年第9期795-796,共2页International Journal of Laboratory Medicine

摘　　要：目的检测肝脏疾病患者组织因子途径抑制物（TFPI）、凝血、抗凝指标，并探讨其临床意义。方法TFPI抗原（TFPI-Ag）采用双抗体夹心ELISA抗原测定法，凝血酶原时间（PT）采用凝固法，D-Z．聚体（D-D）采用免疫比浊法检测。结果肝脏疾病患者中TFPI、PT、D-D均高于健康对照组（P分别〈O．05、〈O、01、〈O．01），仅失代偿期肝硬化患者TFPI-Ag降低（P＜0．05）。结论肝脏疾病患者的TFPI、凝血、抗凝指标异常对评价肝脏损伤及判断预后具有重要的临床意义。Objective To study the changes and clinical significance in tissue factor pathway inhibitor （TFPI）, coagulation and anticoagulation activity in patients with liver diseases, and to explore their clinical significance. Methods TFPI antigen （TFPI-Ag） was monitored via ELISA assay, prothrombin time （PT） via a coagulation method, and D-dimer （D-D） by immunoturbidity. Coagulation and anticoagulation parameters for 80 patients were detected by STAGO. Results The levels of TFPI, PT and D-D in patients with hepatocarcinoma, hepatitis and hepatocirrhosis were progressively prolonged than that of controls （P〈0.05,〈0.01, 〈0.01 respectively）. However, TFPI-Ag in decom- pensation stage of hepatocirrhosis was lower （P〈0.05）. Conclusion The abnormality of the TFPI, coagulation and anticoagulation activity has an important significance in liver injure assessment and prognosis evaluation.

关 键 词：肝癌 肝炎 肝硬化 组织因子途经抑制物 凝血酶原时间 D-二聚体 

分 类 号：R446.61[医药卫生—诊断学]